南昌地区2014-2015年ABO、RhD配合型输血与同型输血病例对照研究

发布时间：2018-11-22 10:51

【摘要】：目的通过回顾性分析ABO、RhD配合型输血与同型输血(下简称"配合型输血或同型输血")病例资料,以探讨配合型输血的安全性和有效性。方法对南昌地区2014年1月-2015年12月疾病治疗因素和特殊情况配合型输血的患者基本资料、红细胞计数(RBC)、血红蛋白浓度(Hb)、红细胞比容(Hct)和血小板计数(Plt)等有效性指标和输血前后Hb、间接胆红素(IBi L)、不规则抗体筛查、直接抗球蛋白试验(DAT)和输血不良反应等安全性指标与配比同型输血组进行病例对照分析,以探讨其安全性与有效性。结果 1)配合型输血与同型输血间输血前Hb、患者输血量、平均住院时间差异均不具统计学意义(P0.05);2组输血患者均未发生输血不良反应;2)配合型输血组与同型输血组红细胞输注24 h后患者RBC、Hb、Hct值均明显升高,差异均具统计学意义(P0.05),血小板输注24 h后患者Plt亦明显升高,差异具统计学意义(P0.05);2组间输血24 h后增加值差异均不具统计学意义(P0.05);3)29例配合型输血患者中,输血24 h后IBi L较输血前差异不具统计学意义(P0.05),新生儿溶血病患者未检出新的其它不规则抗体,其它配合型输血患者DAT和不规则抗体均呈阴性;4)12例配合型输血患者输血后24h、d3、d7的Hb、IBi L间差异均不具统计学意义(P0.05),未检测出新的其它不规则抗体。结论配合型输血与同型输血具有同等的安全性和有效性,特殊情况紧急抢救采取配合型输血是一种安全有效的临床输血治疗途径。
[Abstract]:Objective to study the safety and efficacy of ABO,RhD combined transfusion and homologous blood transfusion (hereinafter referred to as "matching blood transfusion or the same type transfusion"). Methods from January 2014 to December 2015, the basic data of patients with combined transfusion of disease factors and special circumstances in Nanchang area, (RBC), hemoglobin concentration of erythrocyte count, (Hb), were analyzed. RBC specific volume (Hct) and platelet count (Plt) and Hb, indirect bilirubin (IBi L), irregular antibody were screened before and after blood transfusion. The safety indexes of direct antiglobulin test (DAT) and transfusion adverse reaction (ADR) were compared with those of the same blood transfusion group to investigate its safety and effectiveness. Results 1) there was no significant difference in the amount of blood transfusion in patients with Hb, before and after blood transfusion between the two groups (P0.05), and no adverse reaction of blood transfusion occurred in the two groups. 2) the RBC,Hb,Hct values of the patients in the matched transfusion group and the same type transfusion group were significantly increased after 24 hours of erythrocyte transfusion (P0.05), and the Plt of the patients after 24 hours of platelet transfusion was also significantly higher than that of the control group (P0.05). The difference was statistically significant (P0.05). There was no significant difference in the increased value between the two groups after 24 hours of blood transfusion (P0.05). 3) in 29 patients with combined transfusion, there was no significant difference in IBi L between 24 hours after transfusion (P0.05), and no new irregular antibodies were detected in patients with neonatal hemolytic disease. DAT and irregular antibodies were negative in other matched blood transfusion patients. 4) there was no significant difference in Hb,IBi L between 12 patients with blood transfusion 24 hours after blood transfusion on day 3 (P0.05), and no new irregular antibodies were detected. Conclusion Co-operative blood transfusion has the same safety and effectiveness as that of the same type of blood transfusion. It is a safe and effective way to treat clinical blood transfusion by emergency rescue under special circumstances.
【作者单位】：南昌大学第一附属医院输血科;解放军总医院;南方医科大学南方医院;
【分类号】：R457.11

【参考文献】